Doxazosin (DrugBank: Doxazosin)
2 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
57 | 特発性拡張型心筋症 | 1 |
67 | 多発性嚢胞腎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01798992 (ClinicalTrials.gov) | September 2000 | 22/2/2013 | Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart | Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart | Idiopathic Dilated Cardiomyopathy | Drug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosin | University of Colorado, Denver | National Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZeneca | Completed | 18 Years | N/A | All | 56 | Phase 4 | United States |